Related Experiment Video
Updated: Jun 20, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Dendritic cell-based vaccines for pancreatic cancer and melanoma
1Moffitt Cancer Center, Tampa, FL 33612, USA. james.mule@moffitt.org
Abstract:
Based on leads from our recent animal studies, we are embarking on a series of new clinical trials to evaluate potential improvements in dendritic cell (DC)-based vaccines for melanoma and pancreatic cancer. The first new strategy involves the use of a powerful chemokine (denoted secondary lymphoid tissue chemokine; SLC/CCL-21), which can both create functioning lymph node-like structures at sites of vaccination with tumor-loaded DCs and dramatically enhance vaccine efficacy in animal tumor models. Using this strategy, we are embarking on a clinical trial in melanoma patients with the intent to create functioning, ectopic, lymph node-like structures to enhance host antitumor immunity. The second strategy, in the setting of pancreatic cancer, involves a gene therapy and immunotherapy combination of a locally administered tumor necrosis factor-alpha gene vector followed by radiation (to induce tumor apoptosis/necrosis) and intratumorally administered monocyte-derived DCs (to uptake and present antigens from dying tumor cells to elicit potent, systemic, antitumor immunity).
Insights
New clinical trials explore dendritic cell (DC) vaccines for melanoma and pancreatic cancer. Strategies include using secondary lymphoid tissue chemokine (SLC/CCL-21) for melanoma and a gene therapy/immunotherapy combo for pancreatic cancer.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Dendritic cell (DC)-based vaccines show promise for cancer immunotherapy.
- Enhancing the efficacy of DC vaccines is crucial for improving patient outcomes.
- Animal studies suggest novel strategies for boosting antitumor immunity.
Purpose of the Study:
- To evaluate improved dendritic cell (DC)-based vaccine strategies in clinical trials for melanoma and pancreatic cancer.
- To assess the potential of secondary lymphoid tissue chemokine (SLC/CCL-21) in enhancing DC vaccine efficacy.
- To investigate a gene therapy and immunotherapy combination for pancreatic cancer treatment.
Main Methods:
- Clinical trials involving melanoma patients using tumor-loaded DCs and SLC/CCL-21 to create lymph node-like structures.
- Pancreatic cancer trial combining tumor necrosis factor-alpha gene therapy, radiation, and intratumoral DCs.
- Utilizing DCs to uptake and present tumor antigens for systemic antitumor immunity.
Main Results:
- Animal studies demonstrated that SLC/CCL-21 enhances DC vaccine efficacy by creating lymph node-like structures.
- The proposed strategies aim to elicit potent, systemic, antitumor immunity.
- Early findings suggest potential for improved host antitumor responses.
Conclusions:
- Novel strategies involving DC vaccines are being investigated in clinical trials for melanoma and pancreatic cancer.
- The use of SLC/CCL-21 and a gene therapy/immunotherapy combination holds promise for enhancing cancer treatment.
- Further research and clinical evaluation are necessary to confirm the efficacy and safety of these approaches.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations